Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Capital Employed (2017 - 2025)

Vistagen Therapeutics' Return on Capital Employed history spans 10 years, with the latest figure at 1.18% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 57.0% year-over-year to 1.18%; the TTM value through Dec 2025 reached 1.18%, down 57.0%, while the annual FY2025 figure was 0.61%, N/A changed from the prior year.
  • Return on Capital Employed for Q4 2025 was 1.18% at Vistagen Therapeutics, down from 1.07% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.17% in Q1 2021 and bottomed at 1.44% in Q3 2023.
  • The 4-year median for Return on Capital Employed is 0.45% (2024), against an average of 0.62%.
  • The largest YoY upside for Return on Capital Employed was 514bps in 2021 against a maximum downside of -111bps in 2021.
  • A 4-year view of Return on Capital Employed shows it stood at 0.42% in 2021, then rose by 7bps to 0.39% in 2023, then plummeted by -55bps to 0.6% in 2024, then plummeted by -95bps to 1.18% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Return on Capital Employed are 1.18% (Q4 2025), 1.07% (Q3 2025), and 0.91% (Q2 2025).